Disparity between tissue and serum calcitonin and carcinoembryonic antigen in a patient with medullary thyroid carcinoma.
Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor of parafollicular or C-cells of thyroid that comprises 5-10% of all thyroid cancers [1, 2]. The neoplastic cells secrete calcitonin, carcinoembryonic antigen (CEA), and chromogranin A. Typically, increased serum levels of these tumor markers permit them to be used for initial diagnosis and long-term disease status surveillance. This article reports a case of sporadic MTC (pT2N0M0) in a young patient with normal serum tumor markers. A 16-year-old woman presented with MTC without evidence for this to be a familial case due to the absence of germline mutations in the RET proto-oncogene and negative family history. Surprisingly, there were normal preoperative serum levels of calcitonin, CEA, and chromogranin A, despite the immunohistochemistry showing strong and diffuse positive staining for these markers. This disparity between serum levels and tumor expression of calcitonin and CEA in MTC is quite rare. The relevant features of this case are discussed in consideration of the published experiences. This case may represent an unique subgroup of MTC with abnormal secretory capacity that requires reliance upon radiological evaluation for evidence of recurrent or disseminated disease, without the diagnostic benefit of serum tumor markers.
Department of Pathology and Laboratory Medicine, University of Kentucky Medical Center, 800 Rose Street, Lexington, KY 40536, USA. dalapat12@gmail.com
Daisy V
DV
Alapat
Kenneth B
KB
Ain
David A
DA
Sloan
Kristin G
KG
Monaghan
Rouzan G
RG
Karabakhtsian
D000293:Adolescent; D014408:Biomarkers, Tumor / Q000097:blood / Q000378:metabolism; D002116:Calcitonin / Q000097:blood* / Q000378:metabolism*; D002272:Carcinoembryonic Antigen / Q000097:blood* / Q000378:metabolism*; D002277:Carcinoma / Q000097:blood / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D018278:Carcinoma, Neuroendocrine; D005260:Female; D006801:Humans; D000090063:Proto-Oncogene Mas; D013964:Thyroid Neoplasms / Q000097:blood / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas; D002116:Calcitonin
Ann Endocrinol (Paris). 2007 Jun;68(2-3):147-53
17391636
Thyroid. 2008 Aug;18(8):895-9
18651801
Tumori. 2008 Jan-Feb;94(1):110-3
18468344
J Clin Endocrinol Metab. 2000 Feb;85(2):919-22
10690910
Virchows Arch. 1998 Sep;433(3):209-15
9769123
Cancer. 1978 Jun;41(6):2226-35
657088
Curr Opin Otolaryngol Head Neck Surg. 2007 Apr;15(2):89-94
17413408
Int J Clin Oncol. 2007 Feb;12(1):63-7
17380445
Thyroid. 2000 Oct;10(10):919-22
11081258
Anticancer Res. 2000 Nov-Dec;20(6D):5257-60
11326706
J Surg Oncol. 2006 Dec 15;94(8):737-47
17131404
World J Surg Oncol. 2006 Dec 21;4:97
17184544
Diagn Cytopathol. 2007 Sep;35(9):597-600
17703444
Acta Anat (Basel). 1989;135(1):17-21
2787574
J Clin Endocrinol Metab. 2007 Feb;92(2):450-5
17119000
Ann R Coll Surg Engl. 2006 Sep;88(5):433-8
17002842
Am J Surg Pathol. 1997 Jul;21(7):754-62
9236831
Int J Biol Markers. 2008 Apr-Jun;23(2):129-31
18629788
J Surg Oncol. 2005 Mar 1;89(3):122-9
15719378
Thyroid. 2004 Nov;14(11):984-5
15678599
Hematol Oncol Clin North Am. 2007 Jun;21(3):475-88; viii
17548035
Arch Intern Med. 1985 Jul;145(7):1248-52
4015274
Mod Pathol. 2003 Aug;16(8):756-63
12920219
Thyroid. 2004 Jun;14(6):468-70
15242577
Cancer. 1988 Feb 15;61(4):806-16
2448025
Mod Pathol. 1997 Jan;10(1):7-11
9021721
Acta Cytol. 2006 Jan-Feb;50(1):84-7
16514846
Thyroid. 2008 Aug;18(8):889-94
18651827